Company Search:
Advanced Search
Sponsored Links
Oncoarendi Therapeutics SA Company Snapshot
Oncoarendi Therapeutics SA operates within the Biological products exc. diagnostic sector. In addition to historical fundamental analyses, the complete report available to purchase compares Oncoarendi Therapeutics SA with three other pharmaceutical manufacturers in Europe: Biomed Lublin Wytwornia Surowic I Szczepionek SA (2020 sales of 40.16 million Polish New Zlotys [US$10.56 million] of which 100% was Traditional Segment), Biosearch SA of SPAIN (25.84 million Euros [US$30.94 million] of which 40% was Lipids), and Transgene which is based in FRANCE (9.34 million Euros [US$11.19 million] of which 68% was Research & Development Tax Credit).

Sales Analysis.
Company ReportsSubscriptions
Looking For More?
Purchace an In-Depth Report
Oncoarendi Therapeutics SA
  Stock Performance Chart for Oncoarendi Therapeutics SA
  Stock Data: Recent Stock Performance:
  Current Price (4/9/2021): 53.60
(Figures in Polish New Zlotys)
1 Week 3.7%   13 Weeks 1.9%  
4 Weeks -10.7%   52 Weeks 315.5%  
Oncoarendi Therapeutics SA Key Data:
  Ticker: OAT Country: Poland
  Exchanges: WAR Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Biological Products Exc. Diagnostic
  2020 Sales 122,936,400
(Year Ending Jan 2021).
Employees: 84
  Currency: Polish New Zlotys Market Cap: 728,960,000
  Fiscal Yr Ends: December Shares Outstanding: 13,600,000
  Share Type: AKCJE Closely Held Shares: 1,897,267
Feedback | Terms and Conditions | Privacy Policy | Site Index
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.